takeaway
continu deliv except growth ahead alreadi high
expect case volum y/i handili beat upsid
revenu growth outlook also tick despit less favor fx con
see multipl driver support sustain multi-yr growth
valuat remain hang-up ytd move think
stock may take breather nt grow multipl maintain buy
except growth momentum persist post anoth big beat
revenu growth organ vs consensu invisalign volum rose
y/i vs street higher util new user reflect acceler
 stack comp ep consensu revenu upsid better
margin line fx loss off-set lower tax rate
stand-out teen ou i-tero teen case grew y/i ou
outpac adult seventh straight quarter volum mix
grew y/i unbridl momentum across emea apac i-tero
scanner rev surg help initi china launch shipment heartland
biggest us dso also disclos aspen dental dso us adopt i-tero
locat start
competit landscap remain benign anecdot note level
interest new competit launch appear mute real sign momentum
recent entrant view remain moat much wider appreci
competit stori anyway given vastli untap market unlik
rattl growth trajectori time soon
outlook nudg higher despit less favor fx figur rel prior
outlook expect revenu growth vs prior
larg higher i-tero growth invisalign revs/volum growth still seen
opm guidanc also better slightli vs prior flat/up
forecast i-tero scanner rev bullish lead indic futur invisalign
stock big run past month post-aao major
nt competit threat bullish investor day increas lt guidanc think may
consolid bit rel line guid margin rais outlook
said see plenti reason optim look mandibular palat expans
i-tero uptak ou new featur remain bullish multi-yr growth outlook
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
revenu invisalign case
expect achiev sustain above-averag
organ revenu growth improv profit
owe highli differenti product offer
greenfield intenational market expans initi
new competit entrant may emerg
beyond algn moat wider perceiv
view
invisalign penetr new greenfield intenational market
fda approv mandibular us
addit traction i-tero larg dso
nopat compound-annual-growth-rate next decad
price impli ev ebitda
ramp dso relationship
asp eros advers mix shift fx
diminish return increment commerci
page
pleas see import disclosur inform page report
